Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 17 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Neoplasm Metastasis 2 Recurrence 1 Pheochromocytoma 1 Paraganglioma 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Glioblastoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Carboplatin 28 pembrolizumab 21 Paclitaxel 20 Cisplatin 20 Pemetrexed 17 Gemcitabine 10 durvalumab 9 Nivolumab 9 osimertinib 8 130-nm albumin-bound paclitaxel 8 Everolimus 7 Docetaxel 7 Sunitinib 6 Sorafenib 6 Fluorouracil 5 Cetuximab 5 Axitinib 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 reolysin 3 liposomal doxorubicin 3 lenvatinib 3 epothilone B 3 catumaxomab 3 brigatinib 3 Trastuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07227402 2026-03-16

LITESPARK-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡